These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24988441)

  • 1. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
    Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
    PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
    Lees JS; Dobbin SJH; Elyan BMP; Gilmour DF; Tomlinson LP; Lang NN; Mark PB
    Nephrol Dial Transplant; 2023 Jun; 38(7):1666-1681. PubMed ID: 36318455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Evans JR
    Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
    Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
    Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Brunetti M
    Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.
    Neves KB; Rios FJ; Jones R; Evans TRJ; Montezano AC; Touyz RM
    Cardiovasc Res; 2019 Apr; 115(5):978-988. PubMed ID: 30753341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
    Zhu X; Wu S; Dahut WL; Parikh CR
    Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular toxicity associated with anti-angiogenic drugs.
    Neves KB; Montezano AC; Lang NN; Touyz RM
    Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
    Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
    Abdel-Qadir H; Ethier JL; Lee DS; Thavendiranathan P; Amir E
    Cancer Treat Rev; 2017 Feb; 53():120-127. PubMed ID: 28104567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.
    Kovalenko I; Lynn Ng W; Geng Y; Wang Y; Msaouel P; Bhatia S; Grivas P; Benkhadra R; Alhalabi O
    Front Oncol; 2023; 13():1238517. PubMed ID: 38239644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension.
    van Doorn L; Visser WJ; van Dorst DCH; Mirabito Colafella KM; Koolen SLW; de Mik AVE; Garrelds IM; Bovée DM; de Hoop EO; Bins S; Eskens FALM; Hoorn EJ; Jan Danser AH; Mathijssen RHJ; Versmissen J
    Br J Cancer; 2023 Jan; 128(2):354-362. PubMed ID: 36357702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
    Horsley L; Marti K; Jayson GC
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Wang H; Xu T; Zheng L; Li G
    Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.